Wells Fargo Maintains Overweight on ORIC Pharmaceuticals, Lowers Price Target to $23

Benzinga · 1d ago
Wells Fargo analyst Derek Archila maintains ORIC Pharmaceuticals (NASDAQ:ORIC) with a Overweight and lowers the price target from $25 to $23.